BMS-986453 / BMS - LARVOL DELTA

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Susan Bal | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2043 ➔ Dec 2041 | Trial primary completion date: Jan 2028 ➔ Dec 2031

Enrollment open • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: Susan Bal

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Trial completion date: Nov 2027 ➔ May 2030 | Trial primary completion date: Nov 2027 ➔ May 2030

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology